Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05564780 | NOT YET RECRUITING | Cardiovascular Diseases

Study of Early Pharmaceutical Intervention for Cardiovascular Disease Prevention in Stage 1 Hypertension
Sponsor:

Chinese Academy of Medical Sciences, Fuwai Hospital

Information provided by (Responsible Party):

Jun CAI

Brief Summary:

STEP-Pre is to investigate the benefits of using anti-hypertensive drugs in the population with a blood pressure of 130-139/80-89 mmHg and evaluate the health economics. STEP-Pre is a multi-center randomized clinical trial. The cohort will be randomized into the treatment group or control group with a 1:1 ratio. The treatment group will take anti-hypertensive medicine to control blood pressure under 130/80 mmHg. Both groups will take health care education. STEP-Pre will last 4 years.

Condition or disease

Cardiovascular Diseases

Intervention/treatment

RASI and/or a single pill combination based RASI

Phase

NA

Study Type : INTERVENTIONAL
Estimated Enrollment : 20000 participants
Masking : SINGLE
Primary Purpose : PREVENTION
Official Title : Study of Early Pharmaceutical Intervention for Cardiovascular Disease Prevention in Stage 1 Hypertension
Actual Study Start Date : 2023-01-01
Estimated Primary Completion Date : 2026-12-31
Estimated Study Completion Date : 2026-12-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 35 Years to 64 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Stage 1 hypertension (blood pressure is in 130-139/80-89 mmHg);
  • * 35 - 64 years old
  • * Without taking antihypertensive medicine during screening
  • * Signed the written informed consent
Exclusion Criteria
  • * took antihypertensive medicine within the last 1 month;
  • * History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not lacunar infarction and transient ischemic attack \[TIA\]);
  • * History of myocardial infarction or unstable angina or history of coronary revascularization (PCI or CABG);
  • * Lab tests indicating abnormal liver or kidney function (ALT ≥ 3 times the upper limit of normal value, or estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m2);
  • * History of sustained atrial fibrillation or Ventricular arrhythmias at entry influencing the measurement of electronic blood pressure；
  • * Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial;
  • * Dilated or hypertrophic cardiomyopathy, rheumatic heart disease, or congenital heart disease;
  • * Severe somatic disease such as cancer;
  • * Severe cognitive impairment or mental disorders;
  • * pregnant or breastfeeding, or planning to be pregnant;
  • * having organ transplantation;
  • * Participating in other clinical trials.
Study of Early Pharmaceutical Intervention for Cardiovascular Disease Prevention in Stage 1 Hypertension

Location Details

NCT05564780

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

No Location Found